Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $7.28, 31% below $10.60, its close on the day of its Nov 6 underwritten offering. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$81.8MCash on Hand
17.2mo Cash Runway
Follow DTIL by emailGet an email when DTIL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DTIL, unsubscribe in one click. Privacy
📣 What DTIL Says Is Next
second half of 2027 · “Precision anticipates generating initial open-label data from the Phase 2 study in the second half of 2027.”
Company press release, Nov 5, 2026 · SEC filing
first quarter of 2027 · “The Company expects to initiate dosing in the ELIMINATE-B2 Phase 2 study in the first quarter of 2027, with enrollment planned across multiple continents.”
Company press release, Nov 5, 2026 · SEC filing
year-end 2026 · “Initial safety data are targeted for year-end 2026, with efficacy data at distinct timepoints expected to follow in H1 and H2 2027.”
Company press release, Nov 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Financing Precision BioSciences said it sold 10,235,077 common shares at $7.75 each, with pre-funded warrants for up to 5,893,964 shares offered instead of common stock to certain investors, and expects cash runway into the fourth quarter of 2029. Form 8-K · SEC filing
Nov 6, 2026 ·
Financing Precision BioSciences priced an underwritten offering of 10,235,077 common shares at $7.75 per share plus pre-funded warrants for up to 5,893,964 shares, with expected net proceeds of about $116.5 million. Proceeds will fund PBGENE-HBV and PBGENE-DMD and working capital. Closing is expected November 6, 2026. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Clinical trial Precision BioSciences reported updated Phase 1 ELIMINATE-B data for PBGENE-HBV, with undetectable pgRNA in 100% of evaluable patients at 0.4 mg/kg, and plans a Phase 2 study starting in Q1 2027. Results were presented at AASLD on Nov 8, and a webcast is set for Nov 9. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 3, 2026 ·
Earnings Reported Q3 2026 results with $108 million in cash as of September 30, 2026, expected to fund operations through 2028. First patient dosed in the FUNCTION-DMD study, with initial safety data targeted for year-end 2026. PBGENE-HBV late-breaking presentation set for November 8. Form 8-K · SEC filing · Press release
Aug 24, 2026 ·
Clinical trial Dosed the first patient in the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy, at Arkansas Children's Hospital. The company expects initial safety data by year-end 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Recruiting · Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B Registry primary completion date, not a results date
Nov 2029 · Phase 1/2 · Recruiting · PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not DTIL's own candidates): Cyclophosphamide, Nirogacestat.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
DTIL holds $81.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.3M/quarter from operations,
an estimated runway of 17.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:38 · Moderate
Cash runway 17 months +18
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Dec 2025) +10
Company says cash lasts through 2028 -15“ Risk Factors ,” we believe that, as of the date of this Quarterly Report on Form 10-Q, existing cash and cash equivalents, continued fiscal and operating discipline, and availability of our at-the-market (“ATM”) facility will be sufficient to fund our operating expenses and capital expenditure requirements through…10-Q, Nov 2026
Share count +111% in a year +20
Raised after last reported balance sheet (Nov 2026) -10
Share count 27,935,719 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DTIL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DTIL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.